A few answers, many more questions
So far, the team has observed epigen-laden nanolumina in aggressive luminal B and triple-negative breast cancer cells. Basal-like 2 triple negative breast cancer, which is difficult to treat, had nanolumina with particularly high amounts of epigen.
Cheung and Wrenn hope to launch a clinical trial to identify drugs (ones that are already FDA-approved, if possible) that can tamp down the epigen.
“We’ll either break open the nanolumina so everything leaks out, or add drugs that can block the epigen signaling,” Wrenn said. “There’s not an anti-epigen drug, but we’re trying to make one. If we keep these clusters from having this secret, highly concentrated pro-growth signal, they should stop growing or grow less. And that would be beneficial for patients.”
This type of trial, of course, is still years away. For now, they need to answer basic questions.
“We know that breast cells have nanolumina, but we don’t know if prostate or liver cells do,” said Wrenn. “That’s an important question to answer. We’re talking about using this to treat a subset of a subset of cancers [basal-like 2 triple-negative breast cancer], but if we find it in another cancer, there would be that many more people this could help.”
Wrenn said she’s interested in getting "50 different patient tumors from different cancers and see if they have nanolumina, see how widespread these structures are.” She even encouraged researchers outside the Hutch to conduct their own investigations of this no-longer-secret intercellular space.
“That would tell us a lot about the underlying biology and who might benefit from this type of treatment,” she said.
Opening up the ‘locked box’
Cheung said it’s also crucial to discern normal cell function and signaling from normal growth signals that are being co-opted. Cancer has a reputation for “stealing” normal biological functions. Cheung thinks nanolumina may play a role in normal development that’s being co-opted to drive metastasis.
Wrenn explained it like this:
“It may be that when a normal mammary gland is growing, it has nanolumina and epigen which tells it in a normal healthy context, ‘You’re supposed to grow,’” she said. “But then the cancer cells take that and use it inappropriately. They use the same signals for normal growth but it’s not coordinated and regulated the right way. That’s when you get a tumor.”
In other words, cancer hijacks a mammary cell’s “puberty programming” and uses it to grow tumors instead of breasts.
Through patient tissue samples, Cheung has determined that nanoluminal spaces are different between patients, are different with metastatic progression and are different with therapy. And, he added, there may be other potential targets, other growth factors run amok, lurking within these unexplored spaces.
“It’s like a treasure chest or a locked box,” he said. “Molecules inside this compartment could be particularly important to tumor cells.”
Cheung will be delving into these intercellular signaling molecules further with a new grant award from the National Cancer Institute. He will receive $400,000 per year for an initial five-year stretch, after which he’ll have the opportunity to extend his project for two more years.
“We’re still discovering totally new ways that cancer is growing and communicating, and every time we do, that means we have a new target and new tools that can be used to destroy it,” Wrenn said. “Some of those turn into dead ends, but we only need one to work in order to help a lot of people.”
This research was funded by the Department of Defense, the Burroughs Wellcome Fund, the Breast Cancer Research Foundation, the V Foundation, Phi Beta Psi, Seattle Translational Tumor Research and the National Institutes of Health / National Cancer Institute.
Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.